Strongly agree 0 0 Agree 21 26 Neither agree nor disagree 16 20 Disagree 37 45 Strongly disagree 8 10 Using CDK 4 6 a inhibitors for new patients with metastatic HR b positive, HER2 c negative breast cancer CDK4 6 inhibitor aromatase inhibitor is the treatment of choice 35 43 Defer CDK 4 6 inhibitor to the second line until the pandemic is over in all cases 18 22 Defer CDK 4 6 inhibitor to the second line until the pandemic is over in selected cases 29 35 For new patients with nonvisceral metastasis, what is the treatment of choice in the first line during the COVID 19 pandemic cialis no prescription